Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Director | May 28, 2025 | May 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rani Therapeutics Holdings, Inc.
Report date May 28, 2025 · Filed May 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2035-05-27 | Direct | 50,000 |
Reported balance
After 2025-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2025 Filed May 30, 2025 17:45 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantDirector Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001415889-25-015032 · form4-05302025_090534.xml · derivative · entry 1 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2035-05-27 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 17:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $4.11 | Not disclosed |
DisclosureSEC source: 0000950170-24-137315 · ownership.xml · derivative · entry 2 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 17:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-24-137315 · ownership.xml · derivative · entry 1 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options. Read SEC document |
| May 29, 2024 Filed May 30, 2024 16:10 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000950170-24-066582 · ownership.xml · derivative · entry 1 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071467 · ownership.xml · derivative · entry 2 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $4.11 | Not disclosed |
DisclosureSEC source: 0000950170-23-071467 · ownership.xml · derivative · entry 1 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:03 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001209191-23-033042 · doc4.xml · derivative · entry 1 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 21:20 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | ConversionClass A Common LLC Units · Derivative | 7,694 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047662 · doc4.xml · derivative · entry 4 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 248,929 Underlying: Class A Common Stock · 7,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares"). F5 · shares: The Reporting Person is a General Partner of Rani Investment Corp. Represents 7,694 LLC Units previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F1 · derivative.exercise_date: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares"). F1 · derivative.expiration_date: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares"). F6 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. Represents 248,929 LLC Units held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 21:20 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | ConversionClass A Common Stock | 7,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047662 · doc4.xml · nonDerivative · entry 2 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 72,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares"). F4 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P., VH Moll L.P., and Rani Investment Corp. Represents 52,781 Class A Shares held by InCube Ventures II, L.P, 12,343 Class A Shares held by VH Moll L.P., and 7,694 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 21:20 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | ConversionClass B Common Stock | 7,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047662 · doc4.xml · nonDerivative · entry 1 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 248,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares"). F2 · shares: The Reporting Person is a General Partner of Rani Investment Corp. Represents 7,694 Class B Shares previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F3 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. Represents 248,929 Class B Shares held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these except to the extent of his pecuniary interest therein. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:02 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | SaleClass A Common Stock | 9,210 | $11.62 | $107,020.20 |
DisclosureSEC source: 0001209191-22-046957 · doc4.xml · nonDerivative · entry 2 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 65,124 F1 · shares: The Reporting Person is a General Partner of Rani Investment Corp. Represents Class A Shares held by Rani Investment Corp. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.39 to $11.975, inclusive. F5 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and VH Moll, L.P. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P. and 12,343 shares of Class A Common Stock of the Issuer held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:02 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | SaleClass A Common Stock | 71,042 | $10.51 | $746,651.42 |
DisclosureSEC source: 0001209191-22-046957 · doc4.xml · nonDerivative · entry 1 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 74,334 F1 · shares: The Reporting Person is a General Partner of Rani Investment Corp. Represents Class A Shares held by Rani Investment Corp. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.39 to $11.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (4) to this Form 4. F3 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P., VH Moll, L.P., and Rani Investment Corp. Represents 52,781 shares of Class A Common Stock of the Issuer held by InCube Ventures II, L.P., 12,343 shares of Class A Common Stock of the Issuer held by VH Moll, L.P., and 9,210 shares of Class A Common Stock of the Issuer held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 25, 2022 Filed May 27, 2022 08:30 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 41,416 | $0.00 Strike: $10.89 | $0.00 |
DisclosureSEC source: 0000899243-22-019859 · doc4.xml · derivative · entry 1 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,416 Underlying: Class A Common Stock · 41,416 shares Expires 2032-05-24 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 20:13 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | ConversionClass A Common LLC Units · Derivative | 2,309,490 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002127 · edgar.xml · derivative · entry 4 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 256,623 Underlying: Class A Common Stock · 2,309,490 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares"). F6 · shares: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 LLC Units previously held by InCube Ventures II, L.P. and 80,252 LLC Units previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F1 · derivative.exercise_date: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares"). F1 · derivative.expiration_date: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares"). F6 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 LLC Units previously held by InCube Ventures II, L.P. and 80,252 LLC Units previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 20:13 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | OtherClass A Common Stock | 2,229,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002127 · edgar.xml · nonDerivative · entry 3 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 146,379 F2 · kind: InCube Ventures II, L.P. distributed these shares to its limited partners on a pro rata basis, for no consideration F5 · shares: The Reporting Person is a General Partner of InCube Ventures II, L.P. Represents 2,229,238 Class A Shares previously held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F5 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. Represents 2,229,238 Class A Shares previously held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 20:13 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | ConversionClass A Common Stock | 2,309,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002127 · edgar.xml · nonDerivative · entry 2 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 2,375,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares"). F4 · shares: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class A Shares held by InCube Ventures II, L.P. and 80,252 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F4 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class A Shares held by InCube Ventures II, L.P. and 80,252 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 20:13 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | ConversionClass B Common Stock | 2,309,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002127 · edgar.xml · nonDerivative · entry 1 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 256,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares"). F3 · shares: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class B Shares previously held by InCube Ventures II, L.P. and 80,252 Class B Shares previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F3 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class B Shares previously held by InCube Ventures II, L.P. and 80,252 Class B Shares previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 21:41 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | OtherClass A Common Stock | 66,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007637 · doc4.xml · nonDerivative · entry 2 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 66,127 F3 · shares: InCube Ventures II, L.P., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Ventures II, L.P. therefore received 12,289 Class A Shares distributed by Biologix Partners, LP and 41,495 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F4 · shares: VH Moll, L.P., is a limited partner of VH Rani, LP. VH Moll, L.P. therefore received 12,343 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F3 · ownership.nature: InCube Ventures II, L.P., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Ventures II, L.P. therefore received 12,289 Class A Shares distributed by Biologix Partners, LP and 41,495 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F4 · ownership.nature: VH Moll, L.P., is a limited partner of VH Rani, LP. VH Moll, L.P. therefore received 12,343 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 21:41 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | OtherClass A Common Stock | 827,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007637 · doc4.xml · nonDerivative · entry 1 Farquharson Andrew · CIK 0001865699 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Biologix Partners, LP and VH Rani, LP. distributed these shares to its limited partners on a pro rata basis, for no consideration. F2 · shares: Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP. F2 · ownership.nature: Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.